Hemorrhagic-acquired factor XIII deficiency associated with tocilizumab for treatment of rheumatoid arthritis

International Journal of Hematology

Volumn 96, Issue 6, 2012, Pages 781-785

  Matsuoka, Masatake ^a   Majima, Tokifumi ^a   Onodera, Tomohiro ^a   Ieko, Masahiro ^b   Souri, Masayoshi ^c   Ichinose, Akitada ^c   Kurita, Takashi ^a   Kasahara, Yasuhiko ^a   Inoue, Masahiro ^a   Takahashi, Daisuke ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HEALTH SCIENCES UNIVERSITY OF HOKKAIDO   (Japan)

^c YAMAGATA UNIVERSITY   (Japan)

Author keywords

Acquired factor XIII deficiency; Biologics; Bleeding disorder; Rheumatoid arthritis

Indexed keywords

BLOOD CLOTTING FACTOR 13 CONCENTRATE; C REACTIVE PROTEIN; CYCLOSPORIN; FIBRINOGEN; FIBROGAMMIN P; METHOTREXATE; METHYLPREDNISOLONE; TOCILIZUMAB; UNCLASSIFIED DRUG; BLOOD CLOTTING FACTOR 13; IL6 PROTEIN, HUMAN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 6; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BLOOD CLOTTING FACTOR 13 DEFICIENCY; CASE REPORT; DIFFERENTIAL DIAGNOSIS; DRUG WITHDRAWAL; EMERGENCY WARD; FEMORAL NERVE; FIBRIN CLOT; FIBRINOGEN BLOOD LEVEL; HEMATOCRIT; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INGUINAL REGION; LEG PAIN; LEUKOCYTE COUNT; MALE; MEDICAL HISTORY; MUSCLE WEAKNESS; NERVE PARALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; QUADRICEPS FEMORIS MUSCLE; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; STEROID THERAPY; SUBCUTANEOUS HEMORRHAGE; TOTAL HIP PROSTHESIS; BIOSYNTHESIS; BLOOD; CHEMICALLY INDUCED DISORDER; DOWN REGULATION; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; HEMATOMA; HIP ARTHROPLASTY; MIDDLE AGED; POSTOPERATIVE COMPLICATION;

ANTIBODIES, MONOCLONAL, HUMANIZED; ARTHRITIS, RHEUMATOID; ARTHROPLASTY, REPLACEMENT, HIP; CYCLOSPORINE; DOWN-REGULATION; FACTOR XIII; FACTOR XIII DEFICIENCY; FIBRINOGEN; HEMATOMA; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-6; MALE; METHOTREXATE; METHYLPREDNISOLONE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; SJOGREN'S SYNDROME;

EID: 84875277374     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-012-1191-x     Document Type: Article

References (16)

1. Schwartz ML, Pizzo SV, Hill RL, McKee PA. Human Factor XIII from plasma and platelets. Molecular weights, subunit structures, proteolytic activation, and cross-linking of fibrinogen and fibrin. J Biol Chem. 1973;248:1395-407.
2. Curtis CG, Brown KL, Credo RB, Domanik RA, Gray A, Stenberg P, et al. Calcium-dependent unmasking of active center cysteine during activation of fibrin stabilizing factor. Biochemistry. 1974;13:3774-80.
3. Hsieh L, Nugent D. Factor XIII deficiency. Haemophilia. 2008;14:1190-200.
4. Nijenhuis AV, van Bergeijk L, Huijgens PC, Zweegman S. Acquired factor XIII deficiency due to an inhibitor: a case report and review of the literature. Haematologica. 2004;89:ECR14.
5. Ajzner E, Schlammadinger A, Kerényi A, Bereczky Z, Katona E, Haramura G, et al. Severe bleeding complications caused by an autoantibody against the B subunit of plasma factor XIII: a novel form of acquired factor XIII deficiency. Blood. 2009;113:723-5.
6. Ichinose A. Hemorrhagic acquired factor XIII (13) deficiency and acquired hemorrhaphilia 13 revisited. Semin Thromb Hemost. 2011;37:382-8.
7. Lopaciuk S, Bykowska K, McDonagh JM, McDonagh RP, Yount WJ, Fuller CR, et al. Difference between type I autoimmune inhibitors of fibrin stabilization in two patients with severe hemorrhagic disorder. J Clin Invest. 1978;61:1196-203. (Pubitemid 8324144)
8. Ivaskevicius V, Biswas A, Bevans C, Schroeder V, Kohler HP, Rott H, et al. Identification of eight novel coagulation factor XIII subunit A mutations: implied consequences for structure and function. Haematologica. 2010;95:956-62.
9. Iwasa T, Nakamura K, Ogino H, Itaba S, Akiho H, Okamoto R, et al. Multiple ulcers in the small and large intestines occurred during tocilizumab therapy for rheumatoid arthritis. Endoscopy. 2011;43(1):70-2.
10. European Medicines Agency http://www.medicines.org.uk/EMC/medicine/22311/ SPC/RoActemra+20mg+ml+Concentrate+for+Solution+for+Infusion/.
11. Birnbaum J, Klotz E, Spies CD, Hein OV, Mallin K, Kawka R, et al. The combinations C1 esterase inhibitor with coagulation factor XIII and N-acetylcysteine with tirilazad mesylate reduce the leukocyte adherence in an experimental endotoxemia in rats. Clin Hemorheol Microcirc. 2008;40:167-76.
12. Pabst MJ, Pabst KM, Handsman DB, Beranova-Giorgianni S, Giorgianni F. Proteome of monocyte priming by lipopolysaccharide, including changes in interleukin-1beta and leukocyte elastase inhibitor. Proteome Sci. 2008;6:13. (Pubitemid 351803811)
13. McDevitt NB, McDonagh J, Taylor HL, Roberts HR. An acquired inhibitor to factor XIII. Arch Intern Med. 1972;130:772-7.
14. Milner GR, Holt PJ, Bottomley J, Maciver JE. Practolol therapy associated with a systemic lupus erythematosus-like syndrome and an inhibitor to factor XIII. J Clin Pathol. 1977;30:770-3. (Pubitemid 8192074)
15. Otis PT, Feinstein DI, Rapaport SI, Patch MJ. An acquired inhibitor of fibrin stabilization associated with isoniazid therapy: clinical and biochemical observations. Blood. 1974;44:771-81.
16. Fraccarollo D, Galuppo P, Schraut S, Kneitz S, van Rooijen N, Ertl G, et al. Immediate mineralocorticoid receptor blockade improves myocardial infarct healing by modulation of the inflammatory response. Hypertension. 2008;51:905-14. (Pubitemid 351654703)